Jaume Capdevila
Impact in
- Neurology top 0.1%
- Neuroblastoma Research and Treatments
- Epidemiology top 0.1%
- Neuroendocrine Tumor Research Advances
Papers in
- Epidemiology 94
- Neuroendocrine Tumor Research Advances 94
- Oncology 78
- Lung Cancer Research Studies 58
- Pancreatic and Hepatic Oncology Research 15
- Colorectal Cancer Treatments and Studies 5
- Cancer Immunotherapy and Biomarkers 4
- Co-authors
- Marianne Pavel (22 shared papers)Edward M. Wolin (18 shared papers)Kjell Öberg (3 shared papers)Guido Rindi (18 shared papers)Martyn Caplin (14 shared papers)James C. Yao (7 shared papers)Eric Van Cutsem (6 shared papers)Réza Kianmanesh (4 shared papers)
- Journals
- Journal of Clinical Oncology (30 papers)Annals of Oncology (13 papers)Neuroendocrinology (8 papers)European Journal of Cancer (7 papers)Cancer and Metastasis Reviews (6 papers)
- Partner nations
- SpainUnited StatesUnited Kingdom
In The Last Decade
Jaume Capdevila
125 papers receiving 8.1k citations
Jaume Capdevila's Hit Papers
Peers
Comparison fields: 5 of 105
- Neurology 3.0k
- Epidemiology 6.3k
- Oncology 4.4k
- Gastroenterology 130
- Cancer Research 287
Countries citing papers authored by Jaume Capdevila
This map shows the geographic impact of Jaume Capdevila's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaume Capdevila with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaume Capdevila more than expected).
Fields of papers citing papers by Jaume Capdevila
This network shows the impact of papers produced by Jaume Capdevila. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaume Capdevila. The network helps show where Jaume Capdevila may publish in the future.
Co-authors
The 25 scholars most cited alongside Jaume Capdevila, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 129 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Everolimus for Advanced Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2011 | 2096 |
| 2 | Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Hit paper breakdown → | 2014 | 1302 |
| 3 | ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors Hit paper breakdown → | 2016 | 926 |
| 4 | ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site Hit paper breakdown → | 2016 | 743 |
| 5 | 2010 | 313 | |
| 6 | 2016 | 196 | |
| 7 | 2017 | 194 | |
| 8 | 2016 | 172 | |
| 9 | Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery Hit paper breakdown → | 2023 | 168 |
| 10 | [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study Hit paper breakdown → | 2024 | 145 |
| 11 | 2015 | 109 | |
| 12 | 2017 | 89 | |
| 13 | 2017 | 83 | |
| 14 | A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours. | 2016 | 73 |
| 15 | 2013 | 68 | |
| 16 | 2017 | 65 | |
| 17 | 2021 | 63 | |
| 18 | 2021 | 53 | |
| 19 | 2022 | 51 | |
| 20 | 2013 | 50 |
About Jaume Capdevila
Jaume Capdevila is a scholar working on Epidemiology, Oncology, Neurology, Molecular Biology and Surgery, having authored 129 papers that have together received 8.2k indexed citations. Recurring topics across this work include Neuroendocrine Tumor Research Advances (94 papers), Lung Cancer Research Studies (58 papers), Neuroblastoma Research and Treatments (47 papers), Pancreatic and Hepatic Oncology Research (15 papers), Colorectal and Anal Carcinomas (5 papers), Colorectal Cancer Treatments and Studies (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Cancer Immunotherapy and Biomarkers (4 papers). The work is most often cited by research in Neurology (3.0k citations), Epidemiology (6.3k citations), Oncology (4.4k citations), Gastroenterology (130 citations) and Cancer Research (287 citations). Jaume Capdevila has collaborated with scholars based in Spain, United States and United Kingdom. Frequent co-authors include Marianne Pavel, Edward M. Wolin, Kjell Öberg, Guido Rindi, Martyn Caplin, James C. Yao, Eric Van Cutsem, Réza Kianmanesh, Timothy J. Hobday and Paola Tomassetti. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Neuroendocrinology, European Journal of Cancer and Cancer and Metastasis Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.